$450 Million is the total value of MPM ASSET MANAGEMENT LLC's 15 reported holdings in Q4 2014. The portfolio turnover from Q3 2014 to Q4 2014 was 15.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RDUS | Radius Health, Inc. | $226,894,000 | +85.3% | 5,831,253 | 0.0% | 50.39% | +25.7% | |
| EPZM | EpiZyme, Inc. | $45,549,000 | -30.4% | 2,413,819 | 0.0% | 10.12% | -52.8% | |
| PETX | Aratana Therapeutics Inc. | $37,758,000 | +77.5% | 2,118,845 | 0.0% | 8.38% | +20.4% | |
| PTLA | Portola Pharmaceuticals, Inc. | $34,569,000 | +12.0% | 1,220,672 | 0.0% | 7.68% | -24.0% | |
| NVRO | New | Nevro Corporation | $26,555,000 | – | 686,704 | +100.0% | 5.90% | – |
| TRIV | Trivascular Technologies, Inc. | $22,333,000 | -13.2% | 1,776,692 | 0.0% | 4.96% | -41.1% | |
| CLDN | Sell | Celladon Corporation | $15,635,000 | +40.1% | 800,542 | -25.0% | 3.47% | -5.0% |
| PIP | PharmAthene, Inc. | $11,489,000 | +1.7% | 6,347,614 | 0.0% | 2.55% | -31.0% | |
| PRTO | New | Proteon Therapeutics, Inc. | $10,227,000 | – | 983,381 | +100.0% | 2.27% | – |
| CNAT | Conatus Pharmaceuticals, Inc. | $8,345,000 | +14.4% | 1,192,080 | 0.0% | 1.85% | -22.4% | |
| VSTM | Verastem, Inc. | $7,464,000 | +7.3% | 816,683 | 0.0% | 1.66% | -27.2% | |
| ETRM | EnteroMedics, Inc. | $1,581,000 | +15.5% | 1,113,168 | 0.0% | 0.35% | -21.7% | |
| MSTX | Mast Therapeutics, Inc. | $1,429,000 | 0.0% | 2,551,851 | 0.0% | 0.32% | -32.3% | |
| SGMO | Sangamo Biosciences, Inc. | $342,000 | +40.7% | 22,487 | 0.0% | 0.08% | -5.0% | |
| MGNX | MacroGenics, Inc. | $111,000 | +68.2% | 3,168 | 0.0% | 0.02% | +13.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-02-02
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Chiasma, Inc. | 24 | Q2 2021 | 19.8% |
| Aratana Therapeutics, Inc. | 24 | Q1 2019 | 26.8% |
| Conatus Pharmaceuticals, Inc. | 23 | Q1 2019 | 9.7% |
| Rhythm Pharmaceuticals, Inc. | 19 | Q2 2022 | 69.9% |
| Harpoon Therapeutics, Inc. | 19 | Q3 2023 | 31.9% |
| Syndax Pharmaceuticals, Inc. | 19 | Q3 2020 | 14.5% |
| Radius Health, Inc. | 17 | Q2 2018 | 76.4% |
| TCR2 Therapeutics, Inc. | 17 | Q1 2023 | 29.1% |
| Proteon Therapeutics, Inc. | 17 | Q4 2018 | 3.0% |
| EpiZyme, Inc. | 15 | Q4 2016 | 35.9% |
View MPM ASSET MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-09-07 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-05 |
| 4 | 2023-05-24 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View MPM ASSET MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.